Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279802 | 0.75 | P2RX7 (0.56) | KMT2AP2RX7RAB9ANPC1TSHR | |
| SCHEMBL22395410 | 0.73 | P2RX7 (0.65) | KMT2AP2RX7RAB9ANPC1TSHR | |
| SCHEMBL12517119 | 0.71 | P2RX7 (0.57) | KMT2AP2RX7RAB9ANPC1TSHR | |
| SCHEMBL2270219 | 0.69 | GRM5 (0.54) | P2RX7RAB9ANPC1TSHRMAPK1 | |
| SCHEMBL30794592 | 0.69 | GRM5 (0.54) | P2RX7RAB9ANPC1TSHRMAPK1 | |
| SCHEMBL12517631 | 0.66 | P2RX7 (0.47) | KMT2AP2RX7RAB9ATSHRMAPK1 | |
| SCHEMBL3709911 | 0.66 | SPHK2 (0.70) | KMT2AP2RX7ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1548377 | 0.66 | LMNA (0.59) | KMT2AALDH1A1SMN1; SMN2SPHK2LMNA | |
| SCHEMBL29270879 | 0.63 | KMT2A (1.00) | KMT2ARAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10978860 | 0.62 | RAB9A (0.86) | KMT2ARAB9ANPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | claimed |
| WO-2010129954-A1 | TREATMENT OF ISCHEMIA-REPERFUSION INJURY | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-11-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | KMT2A 4046/4885P2RX7 3369/4885RAB9A 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.